Outlook Therapeutics, Inc. (OTLK) financial statements (2020 and earlier)

Company profile

Business Address 7 CLARKE DRIVE
CRANBURY, NJ 08512
State of Incorp. DE
Fiscal Year End September 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments18232
Cash and cash equivalents18232
Prepaid expense   02
Assets held-for-sale, not part of disposal group11   
Other undisclosed current assets55211
Total current assets:714346
Noncurrent Assets
Finance lease, right-of-use asset2 
Operating lease, right-of-use asset0 
Property, plant and equipment13181617
Restricted cash and investments    0
Other noncurrent assets10011
Total noncurrent assets:44191718
TOTAL ASSETS:1017222124
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities99122113
Accounts payable324115
Accrued liabilities55676
Taxes payable22222
Debt01101
Due to related parties4    
Deferred revenue and credits31
Other undisclosed current liabilities7112056
Total current liabilities:2020322920
Noncurrent Liabilities
Long-term debt and lease obligation40403
Long-term debt, excluding current maturities00002
Finance lease, liability3 
Capital lease obligations300
Operating lease, liability0 
Liabilities, other than long-term debt124476
Deferred revenue and credits45
Financial instruments subject to mandatory redemption, settlement terms, share value, amount8    
Other liabilities44431
Other undisclosed noncurrent liabilities04416 
Total noncurrent liabilities:16811238
Total liabilities:3628435129
Temporary equity, carrying amount6553 
Stockholders' equity
Stockholders' equity attributable to parent(31)(16)(26)(34)(5)
Common stock00100
Additional paid in capital240238190152142
Accumulated deficit(271)(254)(216)(186)(147)
Total stockholders' equity:(31)(16)(26)(34)(5)
TOTAL LIABILITIES AND EQUITY:1017222124

Income statement (P&L) ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Gross profit:78343
Operating expenses(41)(44)(33)(40)(55)
Operating loss:(34)(36)(30)(36)(52)
Interest and debt expense(12)(4)(5)(6)(1)
Loss from continuing operations before equity method investments, income taxes:(46)(40)(35)(42)(53)
Other undisclosed income from continuing operations before income taxes1213 
Loss from continuing operations before income taxes:(45)(38)(34)(38)(53)
Income tax expense (benefit)334(1)(0)
Net loss:(42)(35)(30)(39)(53)
Other undisclosed net income attributable to parent0    
Net loss attributable to parent:(41)(35)(30)(39)(53)
Preferred stock dividends and other adjustments(1)(1)(2) (2)
Other undisclosed net loss available to common stockholders, basic(3)(1)(16)(1)(7)
Net loss available to common stockholders, diluted:(45)(36)(48)(40)(63)

Comprehensive Income ($ in millions)

12/31/2019
TTM
9/30/2019
9/30/2018
9/30/2017
9/30/2016
Net loss:(42)(35)(30)(39)(53)
Comprehensive loss, net of tax, attributable to parent:(42)(35)(30)(39)(53)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: